Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.
about
Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents.
P2860
Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@ast
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@en
type
label
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@ast
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@en
prefLabel
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@ast
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@en
P2093
P2860
P1476
Novel Gefitinib Formulation wi ...... atment of A431 Skin Carcinoma.
@en
P2093
Apurva R Patel
Mandip Singh
Rakesh Singh
Ravi Doddapaneni
Roger Mercer
P2860
P304
P356
10.1007/S11095-015-1771-6
P577
2015-08-19T00:00:00Z